FSTL1 and cirrhosis of liver: MNC therapy could improve liver function in patients with liver cirrhosis.54–56 Our data suggest that FSTL1 also plays an indispensable role in mediating the immunosuppressive capacity and antifibrotic effects of MNCs during therapy.